AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Grifols, S.A.
Video analysis: GRFS
All videosNo video analysis for this stock yet. Request one from our team.
News: GRFS
Analyzing Gilead Sciences (NASDAQ:GILD) & Grifols (NASDAQ:GRFS)
Gilead Sciences (NASDAQ: GILD - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Insider and Institutional Ownership 83.7% of Gilead Sciences shares
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
Oakmark International Small Cap Strategy Q2 2026 Portfolio Update
The portfolio's return was 5.34% (net) for the reporting period. We initiated the following positions: Birkenstock Holding, Dormakaba, Hiab, Reply, SATS Ltd., and Scout24. We eliminated the following positions: Grifols Cl B ADR and Sopra Steria Group.
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the completion of the clinical portion of SPARTA (Study of ProlAstin-C Randomized Therapy with Alpha-1 augmentation; NCT01983241), its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin®-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema associated with alpha-1 antitrypsin deficiency (AATD), also known as alpha-1.
Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
Grifols Q2 Earnings Call Highlights
Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy.
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, GAMUNEX®-C, an intravenous immunoglobulin (IVIg), and XEMBIFY®, its subcutaneous immunoglobulin (SCIg).
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.
Similar companies
-
Henry Schein, Inc.
HSIC
·
NASDAQ
Compare
-
Halozyme Therapeutics, Inc.
HALO
·
NASDAQ
Compare
-
Molina Healthcare, Inc.
MOH
·
New York Stock Exchange
Compare
-
AptarGroup, Inc.
ATR
·
New York Stock Exchange
Compare
-
Globus Medical, Inc.
GMED
·
New York Stock Exchange
Compare
-
DaVita Inc.
DVA
·
New York Stock Exchange
Compare